Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Adult T-cell Leukemia/Lymphoma: early-phase trial registry

3 of 9 indexed Adult T-cell Leukemia/Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Adult T-cell Leukemia/Lymphoma: 9 US clinical trials tracked, 3 recruiting.

Adult T-cell Leukemia/Lymphoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Kyowa Kirin, running 1 of these trials.

Enrollment posture brief

Registry condition adult-t-cell-leukemialymphoma

OPEN 3 | RECR 33% | LATE 0 | EARLY 9 | RANK #1916 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Adult T-cell Leukemia/Ly (th…33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adult T-cell Leukemia/Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adult T-cell Leukemia/Lymphoma is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Adult T-cell Leukemia/Lymphoma trials is spread across many organizations.

    Kyowa Kirin accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Adult T-cell Leukemia/Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 44 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.

  4. Adult T-cell Leukemia/Lymphoma research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 27

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2 63 participants

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

NCT05031897

RECRUITING Phase 2 44 participants

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Jonathan Brammer

NCT07356245

RECRUITING Phase 1 20 participants

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Cancer Institute (NCI)

NCT07388563

ACTIVE NOT RECRUITING Phase 2 155 participants

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Daiichi Sankyo

NCT04703192

ACTIVE NOT RECRUITING Phase 2 48 participants

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

City of Hope Medical Center

NCT03113500

ACTIVE NOT RECRUITING Phase 2 16 participants

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

UNC Lineberger Comprehensive Cancer Center

NCT03264131

COMPLETED Phase 2 71 participants

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Kyowa Kirin

NCT01626664

COMPLETED Early Phase 1 7 participants

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT01184885

COMPLETED Phase 2 4 participants

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Columbia University

NCT01274533

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 7

Named interventions

Most-linked intervention names on Adult T-cell Leukemia/Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Brentuximab Vedotin Drug
2 trials
Cyclophosphamide Drug
2 trials
DHAP Drug
1 trials
gemcitabine plus oxaliplatin Drug
1 trials
KW-0761 Biological
1 trials
CHEP Drug
1 trials
Donor Lymphocyte Infusion Procedure
1 trials
abatacept Drug
1 trials

US sites by state

Facility locations filed on Adult T-cell Leukemia/Lymphoma trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
New York 3 trials
New Jersey 3 trials
California 3 trials
Ohio 2 trials
North Carolina 2 trials
Missouri 2 trials
Maryland 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adult T-cell Leukemia/Lymphoma page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Adult T-cell Leukemia/Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Kyowa Kirin sponsors the most Adult T-cell Leukemia/Lymphoma trials on record, review their full trial history before evaluating a specific study. See Kyowa Kirin's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult T-cell Leukemia/Lymphoma condition card totals 9 registered trials; most-linked intervention Brentuximab Vedotin; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.